A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis
Status:
Completed
Trial end date:
2016-12-22
Target enrollment:
Participant gender:
Summary
Tuberculous meningitis is a severe brain infection which often causes disability and death
even when treated with the best available treatment. Aspirin is a type of anti-inflammation
drug which can reduce the inflammatory response in brains of patients with tuberculous
meningitis, and therefore may decrease some of the most severe outcomes. This study compares
the use of aspirin (at 2 different doses) versus placebo as an additional therapy to the
standard treatment to see if aspirin is safe and helpful in reducing disability and death
from tuberculous meningitis. Patients will be treated with aspirin or placebo for 60 days and
followed up while on standard treatment for 8 months.
Phase:
Phase 2
Details
Lead Sponsor:
Oxford University Clinical Research Unit, Vietnam
Collaborator:
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam